Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Tech Today.
Press releases published on April 30, 2025
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
GlobeNewswire
·
April 30, 2025
Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1 clinical trial for CT-95 PHILADELPHIA, April 30, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“ …
Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
GlobeNewswire
·
April 30, 2025
ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that …
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
GlobeNewswire
·
April 30, 2025
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for …
Altimmune to Participate in the Citizens Life Sciences Conference
GlobeNewswire
·
April 30, 2025
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Citizens Life …
Stallion Uranium Announces Completion of Ground Gravity Survey over Coyote Target
GlobeNewswire
·
April 30, 2025
VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) is pleased to announce the successful completion of a ground gravity survey over its Coyote Target, …
InflaRx to Report First Quarter 2025 Results on May 7, 2025
GlobeNewswire
·
April 30, 2025
JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial …
BioCryst to Present at Upcoming Investor Conferences
GlobeNewswire
·
April 30, 2025
RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: Citizens Life Sciences Conference in New York on Thursday, May 8, …
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
GlobeNewswire
·
April 30, 2025
WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today …
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
GlobeNewswire
·
April 30, 2025
WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer …
Emerita Files NI 43-101 Technical Report for the IBW Project, Marking a 35% Increase in Total Indicated Resources and a 44% Increase in Total Inferred Resources
GlobeNewswire
·
April 30, 2025
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX – V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) reports that it has filed the independent NI 43-101 compliant technical report for its Iberian Belt West Project (“IBW” …
Nusano Names Rachel Culbertson VP of Supply Chain
GlobeNewswire
·
April 30, 2025
WEST VALLEY CITY, Utah, April 30, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, today announced the appointment of Rachel Culbertson as Vice President of Supply Chain. Culbertson’s leadership will be …
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
GlobeNewswire
·
April 30, 2025
RAMSEY, N.J. and BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing …
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
GlobeNewswire
·
April 30, 2025
SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today …
Larimar Therapeutics Reports First Quarter 2025 Financial Results
GlobeNewswire
·
April 30, 2025
FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval planned to be submitted by year-end …
I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025
GlobeNewswire
·
April 30, 2025
ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract for …
XORTX Provides Update on FDA Type B Meeting Request
GlobeNewswire
·
April 30, 2025
● XORTX will focus on key steps to advance a NDA filing for Gout indication ● CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical …
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results
GlobeNewswire
·
April 30, 2025
WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 …
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
GlobeNewswire
·
April 30, 2025
Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial. OKYO Pharma plans to analyze the efficacy data from the 17 patients who …
Wabash Announces First Quarter 2025 Results
GlobeNewswire
·
April 30, 2025
Quarterly revenue of $381 million - lower than prior quarterly outlook range on weaker Transportation Solutions demand. Parts …
PL BioScience Launches World’s Only Patented Gamma-irradiated Human Platelet Lysate
GlobeNewswire
·
April 30, 2025
New high-quality cell growth supplement for cell manufacturing applications including in regenerative medicine and cell therapies Human Platelet Lysate (HPL) offers a safer and sustainable alternative to Fetal Bovine/ Calf Serum (FBS/FCS) Gamma-irradiated …